Journal ArticleDOI
Management of osteosarcoma.
Reads0
Chats0
TLDR
This study heralds a new era of clinical investigation into osteosarcoma, with the promise of valuable biologic insights and rapid evaluation of investigational strategies.Abstract:
Improving cure rates for osteosarcoma continues to be a major challenge. The clinical management of individual patients is exacting and requires a skilled, experienced team including a surgeon, pathologist, oncologist, and radiologist, with support from specialist nurses and rehabilitation teams. Outcomes from treatment have improved little in 20 years and remain disappointing. Chemotherapy for osteosarcoma is among the most grueling of any given for solid tumors, and treatment of the primary tumor is associated with permanent disability of some degree in a significant proportion of patients. New systemic treatments remain beyond the horizon. In recognition of these difficulties, an international cooperation has begun with the opening of a randomized trial, European and American Osteosarcoma (EURAMOS) 1, in Europe and the United States. This study heralds a new era of clinical investigation into osteosarcoma, with the promise of valuable biologic insights and rapid evaluation of investigational strategies. Osteosarcoma should always be treated under the guidance of a specialist team, and we recommend that whenever possible, patients be offered entry into EURAMOS 1 or other well-designed clinical trials.read more
Citations
More filters
Journal ArticleDOI
Osteosarcoma treatment - where do we stand? A state of the art review.
TL;DR: The current state of the art of systemic osteosarcoma therapy is reviewed by focusing on the experiences of cooperative osteosARcoma groups, shedding light on questions and challenges posed by the aggressiveness of the tumor, and potential future directions that may be critical to progress in the prognosis of high-grade osteosArcoma.
Journal ArticleDOI
Incidence and survival of malignant bone sarcomas in England 1979-2007
Jeremy Whelan,Anne McTiernan,Nicola Cooper,Yuen K Wong,Matthew Francis,Sally Vernon,Sandra J. Strauss +6 more
TL;DR: This population‐based study has allowed us to confidently define the English incidence and survival rates of both the commoner bone tumours such as osteosarcoma, and rarer entities such as chordoma as well as groups with inferior outcome.
Journal ArticleDOI
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects
TL;DR: Reducing the complications of osteosarcoma therapy is an important goal that will require the identification of clear prognostic indicators, the development of biologically-based therapies, and improved antidotes for the active anti-osteosARcoma cytotoxic drugs.
Journal ArticleDOI
Challenges in the recruitment of adolescents and young adults to cancer clinical trials.
TL;DR: The adolescent and young adult (AYA) oncology population has seen inferior progress in cancer survival compared with younger children and older adults over the past 25 years, and survival rates are particularly poor for AYA‐specific diseases such as sarcomas.
Journal ArticleDOI
Programmed cell death ligand 1 expression in osteosarcoma.
Jacson Shen,Gregory M. Cote,Edwin Choy,Pei Yang,David C. Harmon,Joseph H. Schwab,G. Petur Nielsen,Ivan Chebib,Soldano Ferrone,Xinhui Wang,Yangyang Wang,Henry J. Mankin,Francis J. Hornicek,Zhenfeng Duan +13 more
TL;DR: It is shown, for the first time, that high levels of PDL1 are expressed in a subset of osteosarcoma, and PDL2 expression is positively correlated with TILs, suggesting this subset of patients may benefit from anti-PD-L1 immunotherapy.
References
More filters
Journal ArticleDOI
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Stefan S. Bielack,Beate Kempf-Bielack,Günter Delling,G. Ulrich Exner,Silke Flege,Knut Helmke,Rainer Kotz,Mechthild Salzer-Kuntschik,M. Werner,Winfried Winkelmann,Andreas Zoubek,Heribert Jürgens,Kurt Winkler +12 more
TL;DR: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis.
Journal ArticleDOI
Preoperative Chemotherapy for Osteogenic Sarcoma: Selection of Postoperative Adjuvant Chemotherapy Based on the Response of the Primary Tumor to Preoperative Chemotherapy
Gerald Rosen,Brenda Caparros,Andrew G. Huvos,Cynthia Kosloff,Anita Nirenberg,Adrienne Cacavio,Ralph C. Marcove,Joseph M. Lane,Bipin M. Mehta,Christian Urban +9 more
TL;DR: The value of thorough histologic examination in predicting survival in responding patients and in helping identify patients whose disease‐free survival rate can be substantially increased if they are given alternative postoperative adjuvant chemotherapy after failing to have a good response to preoperative chemotherapy are demonstrated.
Journal ArticleDOI
Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.
Akinori Takaoka,Sumio Hayakawa,Hideyuki Yanai,Dagmar Stoiber,Dagmar Stoiber,Hideo Negishi,Hideaki Kikuchi,Shigeru Sasaki,Kohzoh Imai,Tsukasa Shibue,Kenya Honda,Tadatsugu Taniguchi +11 more
TL;DR: It is shown that transcription of the p53 gene is induced by IFN-α/β, accompanied by an increase in p53 protein level, and that p53 is critical for antiviral defence of the host.
Journal ArticleDOI
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Paul A. Meyers,Glenn Heller,John H. Healey,Andrew G. Huvos,Joseph M. Lane,Ralph C. Marcove,A. Applewhite,Vaia Vlamis,Gerald Rosen +8 more
TL;DR: Intensive chemotherapy can achieve DFS for a high proportion of patients with osteogenic sarcoma and histologic response to preoperative chemotherapy cannot be assessed at diagnosis, although it is a powerful predictor of DFS.
Journal ArticleDOI
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Paul A. Meyers,Cindy L. Schwartz,Mark Krailo,Eugenie S. Kleinerman,Donna L. Betcher,Mark L. Bernstein,Ernest U. Conrad,William S. Ferguson,Mark C. Gebhardt,Allen M. Goorin,Michael E. Harris,John H. Healey,Andrew G. Huvos,Michael P. Link,Joseph Montebello,Helen Nadel,Michael Nieder,Judith K. Sato,Gene P. Siegal,Michael Weiner,Robert J. Wells,Lester E. Wold,Richard B. Womer,Holcombe E. Grier +23 more
TL;DR: The addition of MTP to chemotherapy might improve EFS, but additional clinical and laboratory investigation will be necessary to explain the interaction between ifosfamide and MTP.
Related Papers (5)
Osteosarcoma treatment - where do we stand? A state of the art review.
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
Paul A. Meyers,Cindy L. Schwartz,Mark Krailo,John H. Healey,Mark L. Bernstein,Donna L. Betcher,William S. Ferguson,Mark C. Gebhardt,Allen M. Goorin,Michael E. Harris,Eugenie S. Kleinerman,Michael P. Link,Helen Nadel,Michael Nieder,Gene P. Siegal,Michael A. Weiner,Robert J. Wells,Richard B. Womer,Holcombe E. Grier +18 more